Inclusion Criteria:

- Aged >/=18 years

- Patients of either sex with B-CLL, who are starting a new pharmacological treatment
for B-Chronic Lymphocytic Leukemia (1st, 2nd, 3rd, 4th)

- Foreseen duration of CLL therapy
- B-Chronic Lymphocytic Leukemia progressive stage A, stage B or C (according to Binet
system), or II-IV (according to Rai system)

- WHO Performance Status
- Life expectancy
- Signed Informed consent for personal data's treatment and availability to fill in the
QoL questionnaire

Exclusion Criteria:

- Patients with any other tumour disease

- Chronic Lymphocytic Leukemia therapy in the last 30 days before V0

- More than 3 previous CLL treatments (the therapy is defined by the drug and/or the
treatment period)

- Previous stem cells transplantation

- Concurrent or in the last 30 days participation to any other clinical trial

- Any medical or psychological conditions that might compromise the capacity to sign
the consent for personal data's treatment or to fill in the QoL questionnaire